FDA Approval Date for Inlyta (axitinib)
Inlyta (axitinib) received its initial U.S. Food and Drug Administration (FDA) approval on January 29, 2013 [1].
What is Inlyta Used For?
Inlyta is a targeted therapy medication approved for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer [1]. It is typically used in patients who have previously received one oral epidermal growth factor receptor (EGFR) inhibitor [1].
How Does Inlyta Work?
Inlyta functions by inhibiting tyrosine kinases, particularly vascular endothelial growth factor receptors (VEGFRs) [1]. By blocking these receptors, Inlyta interferes with angiogenesis, the process by which tumors develop new blood vessels, thereby hindering tumor growth and progression [1].
When Can Inlyta Patents Expire?
The patent landscape for Inlyta is complex. While the initial approval date was in 2013, patent expirations can be influenced by various factors, including patent term extensions and potential litigation. Information on specific patent expiration dates and challenges can be found on resources like DrugPatentWatch.com [2].
Who Manufactures Inlyta?
Inlyta is manufactured by Pfizer Inc. [1].
What Clinical Data Supported Inlyta's Approval?
The FDA approval of Inlyta was based on clinical trial data demonstrating its efficacy in patients with advanced RCC. The pivotal study that supported its approval showed a statistically significant improvement in progression-free survival for patients treated with Inlyta compared to those treated with sorafenib [1].
What are the Common Side Effects of Inlyta?
Common side effects reported with Inlyta include diarrhea, fatigue, hypertension, decreased appetite, nausea, dysphonia, and weight loss [1]. Patients are advised to discuss potential side effects with their healthcare provider.
Can Biosimilars Be Developed for Inlyta?
The development of biosimilars for Inlyta is subject to patent protections and regulatory pathways. Once patents expire and exclusivity periods end, biosimilar versions could potentially be developed and approved, offering alternative treatment options.
How Does Inlyta Compare to Other Treatments for Kidney Cancer?
Inlyta is one of several targeted therapies and immunotherapies available for advanced renal cell carcinoma. Its specific place in therapy depends on factors such as prior treatments, patient characteristics, and physician recommendations. Other treatments may include other tyrosine kinase inhibitors, as well as immunotherapeutic agents [3].
What is the Regulatory Status of Inlyta in Other Regions?
Following its FDA approval, Inlyta has also been approved for use in other major markets, including the European Union. The regulatory timelines and specific indications may vary by region [1].
What Are Patient Concerns Regarding Inlyta?
Patient concerns often revolve around managing side effects, understanding treatment efficacy, and accessing the medication. Open communication with healthcare teams is crucial for addressing these concerns [1].
---
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203553lbl.pdf
2. https://drugpatentwatch.com/
3. National Cancer Institute. (n.d.). Kidney Cancer Treatment (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq